RAM
PPH icon

Revere Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Revere Asset Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-172,958
Closed -$15.6M – 46
2025
Q3 		$15.6M Buy
+172,958
New +$15.1M 5.9% 4

Other funds holding PPH

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Revere Asset Management's PPH Position: Q4 2025 in Review

Revere Asset Management sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2025, closing a stake of 172,958 shares — an estimated $15.6M sold.

Revere Asset Management first reported a position in PPH in Q3 2025 and held it in 1 quarter. The position peaked at $15.6M in Q3 2025. 146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

  • Revere Asset Management reported no remaining VanEck Pharmaceutical ETF position as of Q4 2025 after selling out during the quarter.
  • Revere Asset Management sold 172,958 VanEck Pharmaceutical ETF shares in Q4 2025, an estimated $15.6M.
  • Revere Asset Management first reported a position in VanEck Pharmaceutical ETF in Q3 2025 and held it in 1 quarter.
  • Revere Asset Management's VanEck Pharmaceutical ETF position peaked at $15.6M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on Revere Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.